We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency is asking for feedback on a revised guideline for the treatment of Alzheimer’s disease and other types of dementia. Read More
With the clinical trials industry facing its lowest rates of recruitment and retention, drug developers must incorporate big data and patient voices to improve trial efficiency and hasten innovation, says a new report by the Tufts Center for the Study of Drug Development. Read More
CBER’s Allergenic Products Advisory Committee gave a less than stellar assessment on the outlook of clinical trials for immunotherapies to treat food allergies. Read More
A lack of diversity in clinical studies can have crucial health implications in minority populations, as medicines are launched with little understanding of genetic interactions, researchers and regulators warn. Read More
Over the past decade, the number of privately funded clinical trials has nearly doubled, while the number of government-sponsored studies have fallen, according to a new report from Johns Hopkins University. Read More
Roughly a fifth of cancer clinical trials fail to recruit enough participants, creating a “major barrier to progress” for developing new therapies, according to a paper published in the Journal of the National Cancer Institute. Read More
Tweaking even one part of a clinical trial’s protocol — which happens more than half of the time in global trials — takes a toll on research, according to an analysis from the Tufts Center for the Study of Drug Development. Read More
Roughly a fifth of cancer clinical trials fail to recruit enough participants, creating a “major barrier to progress” for developing new therapies, according to a paper published in the Journal of the National Cancer Institute. Read More